α-galactosidase

α-Galactosidase is an endogenous glycosidase that can break down oligosaccharides and glycolipids containing α-galactoside bonds and can be used in the study of Fabry disease.

Exo-α-Galactosidase, Bacteroides thetaiotaomicron (EC.3.2.1.22), is a glycoside hydrolase enzyme.

Exo-α-Galactosidase Isoenzyme from Bacteroides thetaiotaomicron (EC.3.2.1.22) is a glycoside hydrolase enzyme.

α-Galactosidase, Cellvibrio mixtus (EC 3.2.1.22), is a glycoside hydrolase enzyme capable of hydrolyzing terminal α-galactosyl residues in glycolipids and glycoproteins. It exists in two recombinant forms known as α-galactosidase (INN) and β-galactosidase (INN).

α-Galactosidase, Thermus brockianus (EC 3.2.1.22), is a glycoside hydrolase enzyme that hydrolyzes terminal α-galactosyl groups from glycosides and glycoproteins. There are two recombinant forms of α-Galactosidase, known as α-galactosidase (INN) and β-galactosidase (INN).

α-Galactosidase, positionally specific, Escherichia coli (EC 3.2.1.22), is a glycoside hydrolase enzyme that catalyzes the hydrolysis of α-galactosyl residues from the termini of glycolipids and glycoproteins. It exists in two recombinant forms known as α-galactosidase (INN) and β-galactosidase (INN).

α-Galactosidase, Clostridium cellulolyticum (EC 3.2.1.22), is a glycoside hydrolase enzyme that hydrolyzes α-galactosyl groups at the terminal position of glycolipids and glycoproteins. This enzyme exists in two recombinant forms: α-Galactosidase (INN) and β-Galactosidase (INN).

exo-α-1,2-Galactosidase, Bacteroides thetaiotaomicron, is a glycoside hydrolase.

β-galactosidase mRNA (N1-Methylpseudo-UTP) encodes the bacterial lactose Z gene product, β-galactosidase. This enzyme catalyzes the conversion of β-galactosides into monosaccharides and serves as a universal marker for assessing transfection efficiency. The inclusion of N1-Methylpseudo-UTP reduces the immunogenicity of the generated mRNA.

Beta-galactosidase A (BgaA) is a hydrolase enzyme capable of breaking down lactose.

β-Galactosidase Mutein, E. coli, is a hydrolase enzyme that facilitates the conversion of β-galactosides into monosaccharides. The substrates for various β-galactosidases include ganglioside GM1, lactosylceramide, lactose, and an array of glycoproteins.

Alpha-Galactosidase A is a lysosomal exoglycosidase that hydrolyzes the terminal α-galactose residues of glycoconjugates.

Migalastat hydrochloride (GR181413A) is an orally available, potent and competitive inhibitor of alpha-galactosidase A. It promotes the transport of alpha-galactosidase A to the lysosome and can be used in the study of Fabry disease.

4-Nitrophenyl α-D-galactopyranoside (PNP-alpha-D-Gal) is an artificial substrate of 4-nitrophenyl (pNP) glycopyranoside used for detecting α-galactosidase activity. The amount of released pNP increases significantly when PNP-alpha-D-Gal is used as a substrate.

D-Ribonolactone is a sugar lactone and an inhibitor of β-galactosidase in Escherichia coli (Ki: 26 mM).

Tryptophan, N-indol-3-ylacetyl- (Indole-3-acetyl-L-tryptophan) is involved in regulatory mechanisms for the control of auxin activity during physiological and pathophysiological responses. It may also be used in the synthesis of β-D-galactosidase and β-D-glucosidase inhibitors.

β-Galactosidase (GAL) is a glycoside hydrolase that hydrolyzes the β-glycosidic bond formed between galactose and its organic part, and naturally catalyzes the hydrolysis of the galactosidic bond in oligosaccharides and disaccharides for the degradation of lactose and the production of low-lactose and lactose-free lactose products that are beneficial to lactose intolerant patients.

α-N-acetylgalactosidase (EC 3.2.1.4) is a highly specific exoglycosidase capable of effectively hydrolyzing α-N-acetylgalactosamine (GalNAc) linked to serine or threonine residues in glycoproteins (Tn antigen). This enzyme demonstrates activity towards terminal GalNAc in α 1-3 linkages and operates optimally within a pH range of 6.0-7.6, without requiring cofactors or specialized buffer systems.

Raffinose (Melitriose) is an indigestible short-chain oligosaccharide, a trisaccharide composed of galactose, glucose and fructose, found in many plants. It can be hydrolyzed by α-galactosidase (α-GAL) to D-galactose and sucrose.

X-alpha-Gal is a substrate for alpha-galactosidase. It is used for differentiating alpha-galactosidase-positive strains of yeast.

Globotriaosylceramide (non-hydroxy) (porcine RBC) is a glycosphingolipid found in the cell membranes of mammals. It is a central pathogenic molecule in Fabry disease, with its levels modifiable by supplementing α-galactosidase A. This compound enhances B cell receptor signaling by regulating the localization of the coreceptor CD19 and can serve as a vaccine adjuvant, promoting a broad and cross-protective antibody response. Additionally, Globotriaosylceramide (non-hydroxy) (porcine RBC) aids in wound healing and decreases scar formation by modulating fibroblast heterogeneity.

N-Octyl-α-4-epivalienamine is an orally active molecular chaperone capable of crossing the blood-brain barrier. It induces high expression of defective β-galactosidase activity. This compound improves symptoms and increases survival rates in mouse models of GM1 gangliosidosis. N-Octyl-α-4-epivalienamine is applicable for research in neurogenetic diseases.

DGJ-pFPhT is a ligand of human α-galactosidase A.

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).